The inspection, conducted between April 13 and April 21, 2026, ended with the issuance of a Form 483 carrying five observations.
1 Min Read
Shares of Ajanta Pharma Ltd. were trading largely flat on Wednesday, April 22, after the company informed exchanges that the US Food and Drug Administration (FDA) has concluded an inspection at its manufacturing facility in Paithan, Maharashtra.
The inspection, conducted between April 13 and April 21, 2026, ended with the issuance of a Form 483 carrying five observations.
The company said it will respond to the observations within the stipulated timeline.
Ajanta Pharma shares were last trading 0.16% lower at ₹2,786.80 on Wednesday. The stock is down around 5% so far this year.
